SEQUENCE LISTING

- <110> UTKU, Nalan
- Use of agents derived from CEACAM1 for the treatment of <120> inflammatory diseases
- <130> GE19A56/P-WO
- PCT/EP2004/014435 <140>
- 2004-12-17 <141>
- EP 03 028 968.0 <150>
- 2003-12-17 <151>
- <160> 1

٦

- PatentIn version 3.3 <170>
- <210>
- 526 <211>
- <212> **PRT**
- Homo sapiens <213>
- <220> <221> CEACAM1
- <222> (1)..(526)
- <400> 1
- Met Gly His Leu Ser Ala Pro Leu His Arg Val Arg Val Pro Trp Gln 10 15
- Gly Leu Leu Leu Thr Ala Ser Leu Leu Thr Phe Trp Asn Pro Pro Thr
- Thr Ala Gln Leu Thr Thr Glu Ser Met Pro Phe Asn val Ala Glu Gly
- Lys Glu Val Leu Leu Val His Asn Leu Pro Gln Gln Leu Phe Gly 50 60
- Tyr Ser Trp Tyr Lys Gly Glu Arg Val Asp Gly Asn Arg Gln Ile Val 65 70 75 80
- Gly Tyr Ala Ile Gly Thr Gln Gln Ala Thr Pro Gly Pro Ala Asn Ser 85 90 95
- Gly Arg Glu Thr Ile Tyr Pro Asn Ala Ser Leu Leu Ile Gln Asn Val
- Thr Gln Asn Asp Thr Gly Phe Tyr Thr Leu Gln Val Ile Lys Ser Asp 115 120 125
- Leu Val Asn Glu Glu Ala Thr Gly Gln Phe His Val Tyr Pro Glu Leu
- Pro Lys Pro Ser Ile Ser Ser Asn Asn Ser Asn Pro Val Glu Asp Lys 145 150 155 160 1/3

Asp Ala Val Ala Phe Thr Cys Glu Pro Glu Thr Gln Asp Thr Thr Tyr 165 170 175 Leu Trp Trp Ile Asn Asn Gln Ser Leu Pro Val Ser Pro Arg Leu Gln 180 185 190 Leu Ser Asn Gly Asn Arg Thr Leu Thr Leu Leu Ser Val Thr Arg Asn 195 200 205 Asp Thr Gly Pro Tyr Glu Cys Glu Ile Gln Asn Pro Val Ser Ala Asn 210 215 220 Arg Ser Asp Pro Val Thr Leu Asn Val Thr Tyr Gly Pro Asp Thr Pro 225 230 235 240 Thr Ile Ser Pro Ser Asp Thr Tyr Tyr Arg Pro Gly Ala Asn Leu Ser 255 Leu Ser Cys Tyr Ala Ala Ser Asn Pro Pro Ala Gln Tyr Ser Trp Leu 260 265 270 Ile Asn Gly Thr Phe Gln Gln Ser Thr Gln Glu Leu Phe Ile Pro Asn 275 280 285 Ile Thr Val Asn Asn Ser Gly Ser Tyr Thr Cys His Ala Asn Asn Ser 290 295 300 Val Thr Gly Cys Asn Arg Thr Thr Val Lys Thr Ile Ile Val Thr Glu 305 310 315 320 Leu Ser Pro Val Val Ala Lys Pro Gln Ile Lys Ala Ser Lys Thr Thr 325 330 335 Val Thr Gly Asp Lys Asp Ser Val Asn Leu Thr Cys Ser Thr Asn Asp 340 345 350 Thr Gly Ile Ser Ile Arg Trp Phe Phe Lys Asn Gln Ser Leu Pro Ser 355 360 365 Ser Glu Arg Met Lys Leu Ser Gln Gly Asn Thr Thr Leu Ser Ile Asn 370 375 380 Pro Val Lys Arg Glu Asp Ala Gly Thr Tyr Trp Cys Glu Val Phe Asn 385 390 395 400 Pro Ile Ser Lys Asn Gln Ser Asp Pro Ile Met Leu Asn Val Asn Tyr 405 410 415 Asn Ala Leu Pro Gln Glu Asn Gly Leu Ser Pro Gly Ala Ile Ala Gly

;

Ile Val Ile Gly Val Val Ala Leu Val Ala Leu Ile Ala Val Ala Leu 435 440 445

Ala Cys Phe Leu His Phe Gly Lys Thr Gly Arg Ala Ser Asp Gln Arg 450 460

Asp Leu Thr Glu His Lys Pro Ser Val Ser Asn His Thr Gln Asp His 465 470 475 480

Ser Asn Asp Pro Pro Asn Lys Met Asn Glu Val Thr Tyr Ser Thr Leu 485 490 495

Asn Phe Glu Ala Gln Gln Pro Thr Gln Pro Thr Ser Ala Ser Pro Ser 500 510

Leu Thr Ala Thr Glu Ile Ile Tyr Ser Glu Val Lys Lys Gln 515 525